UNSPSC 51422358: Paramethasone acetate

This classification denotes a therapeutic glucocorticoid with the molecular formula C24H31FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8X50N88ZDP, chemically known as 6alpha-fluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 21-acetate but more generally known as paramethasone acetate, which bears US NIH Compound Identifier 15333. European Medicines Agency schedules Paramethasone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03645MIG.

UNSPSC 51422358 Paramethasone acetate is a Commodity code that does not align with the recent state and local opportunities posted under it. The code nominally describes a specific corticosteroid pharmaceutical ingredient, yet the recent solicitation records show procurement activity for naloxone (an opioid antagonist), drug deactivation systems, and prescription fulfillment program design — none of which are paramethasone acetate or closely related pharmaceutical products. This mismatch suggests either a tagging error in the source data or that the code has been applied to a broader pharmaceutical procurement category in state and local systems that does not reflect its narrow UNSPSC definition.

The two recent opportunities on file come from Seminole County, Florida (IFB 60459723LAS, posted June 30, 2026, with a bid deadline of July 26, 2023) and the Texas Health and Human Services Commission (RFI HHS0017013, posted April 3, 2026). Seminole County seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries to a county health building. The Texas HHS Commission issued a Request for Information to explore direct-to-manufacturer pharmacy prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. Geographic activity appears limited to Florida and Texas in the recent record. The code shows little relevant activity aligned with its nominal pharmaceutical scope and warrants verification against the actual commodities being acquired before pursuing opportunities tagged under it.